Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer

Thymidylate synthase (TYMS) plays a role in DNA synthesis and is a target for 5-fluorouracil. In this study TYMS was analyzed by immunohistochemistry on a tissue microarray containing 11,152 prostate cancers. TYMS expression was higher in neoplastic than in normal prostate epithelium and was detectable in 72.9% of 10,223 interpretable cancers. It was considered strong in 21.9%, moderate in 33.4% and weak in 17.6% of tumors. TYMS overexpression was associated with deletions at 5q21 (p < 0.0001), 6q15 (p < 0.0001) and 3p13 (p = 0.0083) and gradually increased with the total number of these deletions present in the respective cancer sample (p < 0.0001). TYMS expression was unrelated to PTEN deletions (p = 0.9535) but tightly linked to high Gleason grade, advanced pathological tumor stage and early PSA recurrence (p < 0.0001). The prognostic value of TYMS was independent from the ERG status and deletions at 3p13, 5q21, and 6q15. In multivariate analyses the prognostic role of TYMS expression was independent of Gleason grade, pT stage, preoperative PSA, pN stage, or resection margins. TYMS expression analysis might result in clinically useful information in prostate cancer. The striking link to some but not all chromosomal aberrations might suggest a mechanistical link with specific types of DNA damage.

[1]  E. Schaeffer,et al.  Active Surveillance for Prostate Cancer. , 2017, JAMA.

[2]  C. Cano,et al.  Expression Profiling of Rectal Tumors Defines Response to Neoadjuvant Treatment Related Genes , 2014, PloS one.

[3]  H. Walden,et al.  The Fanconi anemia DNA repair pathway: structural and functional insights into a complex disorder. , 2014, Annual review of biophysics.

[4]  Christopher R. Schmidt,et al.  Altered regulation of DNA ligase IV activity by aberrant promoter DNA methylation and gene amplification in colorectal cancer. , 2014, Human molecular genetics.

[5]  Li Ding,et al.  Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.

[6]  G. Brodeur,et al.  Role of CHD5 in human cancers: 10 years later. , 2014, Cancer research.

[7]  E. Santoni-Rugiu,et al.  Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non‐small‐cell lung cancer , 2014, Histopathology.

[8]  S. Lees-Miller.  Faculty Opinions recommendation of HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis. , 2013 .

[9]  C. Tinelli,et al.  Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. , 2013, Anticancer research.

[10]  D. Iizuka,et al.  Loss of the BRCA1-Interacting Helicase BRIP1 Results in Abnormal Mammary Acinar Morphogenesis , 2013, PloS one.

[11]  S. Kurtz,et al.  Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion‐positive prostate cancers , 2013, The Journal of pathology.

[12]  K. Ushijima,et al.  RECQL1 DNA Repair Helicase: A Potential Therapeutic Target and a Proliferative Marker against Ovarian Cancer , 2013, PloS one.

[13]  J. Korbel,et al.  Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.

[14]  E. Scarpi,et al.  Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. , 2013, Clinical colorectal cancer.

[15]  G. Sauter,et al.  CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.

[16]  G. Sauter,et al.  Loss of pSer2448‐mTOR expression is linked to adverse prognosis and tumor progression in ERG‐fusion‐positive cancers , 2013, International journal of cancer.

[17]  S. Bonin,et al.  Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision , 2013, BMC Gastroenterology.

[18]  V. Beneš,et al.  Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.

[19]  George Fountzilas,et al.  Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS) , 2012, BMC Cancer.

[20]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[21]  Y. Cho,et al.  Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer. , 2011, Anticancer research.

[22]  A. Haese*,et al.  The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. , 2011, International journal of oncology.

[23]  Lei Zhang,et al.  DNA Ligase III Promotes Alternative Nonhomologous End-Joining during Chromosomal Translocation Formation , 2011, PLoS genetics.

[24]  A. Haese*,et al.  High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer , 2011, The Prostate.

[25]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[26]  I. Thompson,et al.  Active surveillance for prostate cancer. , 2010, JAMA.

[27]  Asha A. Nair,et al.  The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. , 2010, Cancer research.

[28]  A. Ozawa,et al.  Possibility of using mRNA expression levels for nucleic acid-metabolizing enzymes within prostate cancer cells as indices for prognostic factors. , 2010, Oncology letters.

[29]  L. Ramalho,et al.  Significance of topoisomerase IIIβ expression in breast ductal carcinomas: strong associations with disease-specific survival and metastasis. , 2010, Human pathology.

[30]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[31]  A. Thompson,et al.  DNA polymerase θ up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability , 2010, Proceedings of the National Academy of Sciences.

[32]  Hartwig Huland,et al.  Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer , 2010, Clinical Cancer Research.

[33]  G. Sauter,et al.  Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer , 2009, Clinical Cancer Research.

[34]  H. Pospiech,et al.  Mutations/Polymorphisms in the 55 kDa Subunit of DNA Polymerase ϵ in Human Colorectal Cancer , 2009 .

[35]  J. Eshleman,et al.  Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence. , 2009, Cancer research.

[36]  A. Haese*,et al.  Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.

[37]  J. Köllermann,et al.  Identifizierung und Validierung klinisch relevanter molekularer Veränderungen im Prostatakarzinom , 2008, Der Urologe.

[38]  J. Brooks,et al.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.

[39]  T. Wilt,et al.  Chemotherapy for hormone-refractory prostate cancer. , 2006, The Cochrane database of systematic reviews.

[40]  N. Kinukawa,et al.  High‐grade and hormone‐treated prostate cancer express high levels of thymidylate synthase , 2006, BJU international.

[41]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[42]  A. Birtle,et al.  Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer , 2004, British Journal of Cancer.

[43]  Y. Rustum.  Thymidylate synthase: a critical target in cancer therapy? , 2004, Frontiers in bioscience : a journal and virtual library.

[44]  M. Kornmann,et al.  Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review , 2004, Langenbeck's Archives of Surgery.

[45]  F. Kaye,et al.  Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. , 2004, Cancer cell.

[46]  A. Matakidou,et al.  Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[48]  M. Fukushima,et al.  Significance of thymidylate synthase activity in renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  R. Martino,et al.  Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. , 2002, The oncologist.

[50]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[51]  R. Gelber,et al.  Prognostic importance of thymidylate synthase expression in early breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  A. Benson,et al.  A phase II study of continuous infusion 5‐fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study , 1993, Cancer.

[53]  N. Mor,et al.  Unforeseen death of Mycobacterium lepraemurium in infected susceptible mice. , 1986, The Journal of infectious diseases.

[54]  Amanda,et al.  Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. , 1980, The Journal of biological chemistry.

[55]  E. He,et al.  The proliferation marker thymidine kinase 1 in clinical use. , 2013, Molecular and clinical oncology.

[56]  H. Pospiech,et al.  Mutations/polymorphisms in the 55 kDa subunit of DNA polymerase epsilon in human colorectal cancer. , 2009, Cancer genomics & proteomics.

[57]  J. Köllermann,et al.  [Identification and validation of clinically relevant molecular alterations in prostate cancer]. , 2008, Der Urologe. Ausg. A.

[58]  M. Fukushima,et al.  Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy. , 2007, Urology.

[59]  P. Danenberg,et al.  Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer , 2005, Prostate Cancer and Prostatic Diseases.

[60]  D. Santi,et al.  The catalytic mechanism and structure of thymidylate synthase. , 1995, Annual review of biochemistry.